Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/21/2017 02/22/2017 02/23/2017 02/24/2017 02/27/2017 Date
86.55(c) 85.79(c) 85.73(c) 86.07(c) 88.9(c) Last
1 665 274 1 263 166 890 750 1 406 789 2 073 654 Volume
-2.02% -0.88% -0.07% +0.40% +3.29% Change
More quotes
Financials ($)
Sales 2017 2 037 M
EBIT 2017 419 M
Net income 2017 148 M
Finance 2017 876 M
Yield 2017 -
Sales 2018 2 547 M
EBIT 2018 807 M
Net income 2018 501 M
Finance 2018 1 700 M
Yield 2018 -
P/E ratio 2017 115,13
P/E ratio 2018 43,39
EV / Sales2017 10,1x
EV / Sales2018 7,71x
Capitalization 21 348 M
More Financials
Company
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases.It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS INC
02/24 VERTEX PHARMACEUTICALS INCORPORATED : Reports Summarize Gastroenterology Study R..
02/23 VERTEX PHARMACEUTICALS INCORPORATED : INC / MA MANAGEMENT'S DISCUSSION AND ANALY..
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/07 VERTEX PHARMACEUTICALS INCORPORATED : Stock Price of Vertex Pharmaceuticals Inco..
01/28 VERTEX PHARMACEUTICALS INCORPORATED : U.S. Patents Awarded to Inventors in Calif..
01/28 INGERSOLL RAND : U.S. Patents Awarded to Inventors in New Jersey (Jan. 28)
01/25 VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
01/25 VERTEX PHARMACEUTICALS INCORPORATED : tops Street 4Q forecasts
01/25 VERTEX PHARMACEUTICALS INCORPORATED : Reports Full-Year and Fourth-Quarter 2016 ..
More news
Sector news : Bio Therapeutic Drugs
08:06aDJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/25Teachers Retirement System of The State of Kentucky Lowers Stake in Vertex Ph.. 
02/24$VRTX .. MAR 90 CALL Activity .. 1800+ @$1.85-2.00 on OFFER .. Expire MAR 17
2
02/23Vertex Pharmaceuticals: Avoid This Cash Vortex  
02/22Gilead's M&A Growth Strategies Becoming Increasingly Limited
1
02/22Metropolitan Life Insurance Co. NY Has $9,902,000 Position in Vertex Pharmace.. 
More tweets
Qtime:107
News from SeekingAlpha
02/23 VERTEX PHARMACEUTICALS : Avoid This Cash Vortex
02/22 Gilead's M&A Growth Strategies Becoming Increasingly Limited
02/21 This Biotech ETF Looks Primed To Rally Again
02/09 Buying Growth Is A Tricky Choice For Gilead
02/09 Darzalex And Keytruda Win 2016's Sell-Side Popularity Contest
Advertisement
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 99,0 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith EVP, Chief Operating & Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Joshua S. Boger Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..16.83%21 348
AMGEN, INC.19.39%128 555
GILEAD SCIENCES, INC.-2.33%92 143
CELGENE CORPORATION2.14%91 979
REGENERON PHARMACEUTIC..-1.66%38 296
ACTELION LTD22.36%28 792
More Results